Myriad Genetics
MYGN
232 hedge funds and large institutions have $3.86B invested in Myriad Genetics in 2015 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 75 increasing their positions, 95 reducing their positions, and 30 closing their positions.
13% more capital invested
Capital invested by funds: $3.41B → $3.86B (+$450M)
1% less funds holding
Funds holding: 234 → 232 (-2)
3% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 30
7% less call options, than puts
Call options by funds: $14.2M | Put options by funds: $15.4M
21% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 95
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
+$84.4M |
| 2 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$28.7M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$26.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.7M |
| 5 |
Morgan Stanley
New York
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$90.8M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$58.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$43.8M |
| 4 |
RA
Royce & Associates
New York
|
-$36.2M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$26.1M |
MYGN Hedge Fund Activity: Q4 2015 in Review
232 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2015, worth a combined $3.86B — up 13% from $3.41B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of MYGN and 29 opened new positions — a net loss of 1 holder — while 95 trimmed existing stakes and 75 added.
The largest buyer was RS Investment Management, opening a new position worth an estimated $84.4M. The largest seller was Capital World Investors, cutting an estimated $90.8M.
- 232 institutional investors held Myriad Genetics (MYGN) as of Q4 2015, down from 234 in Q3 2015.
- Funds reported $3.86B of Myriad Genetics stock for Q4 2015, up 13% quarter-over-quarter.
- 29 funds opened new Myriad Genetics positions in Q4 2015 and 30 closed out, a net change of -1 holder.
- The largest Myriad Genetics buyer in Q4 2015 was RS Investment Management, an estimated $84.4M added.
- The largest Myriad Genetics seller in Q4 2015 was Capital World Investors, an estimated $90.8M sold.
Based on aggregated 13F filings for Q4 2015.